Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05500092 · ClinicalTrials.gov registry record · Phase 2
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
A Phase 2 study of Resectable Stage IIA to IIIB Non-small Cell Lung Cancer, sponsored by Montefiore Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT05500092 is a Phase 2 study of Resectable Stage IIA to IIIB Non-small Cell Lung Cancer that is active but no longer recruiting, run by Montefiore Medical Center. The registered enrollment target is 17 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT05500092, a Phase 2 study of Resectable Stage IIA to IIIB Non-small Cell Lung Cancer, is active but no longer recruiting, sponsored by Montefiore Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
Conditions Studied
Interventions
- DRUG Nivolumab
- RADIATION (8gy x 3)
- DRUG Platinum Doublet
Study Locations (4)
New York
- Montefiore Medical Center-Albert Einstein College of Medicine - The Bronx
- White Plains Hospital (WPH) - White Plains
Missouri
- Washington University in St. Louis - St Louis
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05500092
The ClinicalTrials.gov registry entry for NCT05500092 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Resectable Stage IIA to IIIB Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT05500092 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05500092 about?
NCT05500092 is a clinical study titled "An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer". An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
What is the current status of trial NCT05500092?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2023-01-25. Estimated completion is 2030-05.
What conditions does trial NCT05500092 study?
This clinical trial studies the following conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT05500092?
The interventions under investigation include: Nivolumab (DRUG), (8gy x 3) (RADIATION), Platinum Doublet (DRUG).
Who is sponsoring clinical trial NCT05500092?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05500092 being conducted?
This trial has 4 study locations across Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.